萘丁美酮或萘普生与甲氨蝶呤合用治疗类风湿关节炎的不良反应比较

Contrast of the adverse drug reactions to the treatment of rheumatoid arthritis with combination of nabumetone or naproxen and methotrexate

目的 比较非甾体抗炎免疫药 (NSAIDs)与慢作用抗风湿病药 (SAARDs)合用治疗类风湿关节炎 (RA)的不良反应发生情况。方法 对萘丁美酮 (NAB) +甲氨蝶呤 (MTX)和萘普生 (NAP) +MTX两组病人采用问卷方式进行调查 ,同时查阅病人的病历和各种化验单。资料采用Epiinfo软件进行统计分析。 结果 两组病人治疗后的不良反应出现率除胃痛的差异有显著性 (P <0 0 5 )外 ,其余的不良反应出现率之间的差异均无显著性 (P >0 0 5 )。结论 在RA治疗上常采用的NSAIDs与SAARDs合并用药中 ,并未体现出COX 2选择性抑制剂NAB合用MTX在不良反应方面优于NAP合用MTX。

AIM Contrast of the adverse drug reaction to the treatment of patients with rheumatoid arthritis by combination of nabumetone (NAB) or naproxen (NAP) and methotrexate (MTX). METHODS By questionnaires among the two groups taking nabumetone plus methotrexate or naproxen plus methotrexate respectively, meanwhile, consulting their medical records and their various lab test reports. All these data were figured out and analyzed by Epi info.RESULT After treatment of illnesses, there is no obvious difference ( P >0 05) except in the case of stomachache ( P <0 05) among the two groups.CONCLUSION There is no indication that COX-2 alternative inhibitor NAB combined with MTX is superior to NAP combined with MTX in adverse drug reactions.